3.215.190.193
dgid:
enl:
npi:0
-Advertisement-
-Advertisement-
Conference Roundup

Bimatoprost implant demonstrates extended IOP lowering duration of IOP

Posted on

Some patients treated with the bimatoprost implant demonstrated a sustained IOP lowering and requires no IOP-lowering treatment for ≥2 years after their last administration in a phase 3 trial, according to a study presented at ARVO 2021.

Biodegradable, intracameral bimatoprost implant slowly releases bimatoprost for 3 to 4 months to lower IOP. This analysis evaluated the duration of IOP control provided by the implant in a 24-month, ongoing, open-label, multicenter, long-term safety and efficacy extension study that optionally enrolled patients with open-angle glaucoma or ocular hypertension after their completion of a bimatoprost implant phase 3 clinical trial. The study included patients who had received 10- or 15-µg bimatoprost implant in the study eye on Day 1 and Weeks 16 and 32 in a 20-month, randomized, phase 3 ARTEMIS trial. The analysis evaluated IOP and the number of patients who received no additional (rescue) IOP-lowering treatment in the study eye for ≥2 years after the last implant administration during the ARTEMIS trial.

Among 181 implant-treated patients who completed ARTEMIS and enrolled in the study extension, 48 had not been rescued at the study extension screening, and 32 did not require rescue for ≥2 years after their last implant administration. For these 32, mean (±SD) time without rescue after the last implant administration was 2.6 ± 0.5 years, and mean (±SD) IOP was 23.4 ± 1.9 mm Hg at initial (ARTEMIS study) baseline and 18.1 ± 3.1 mm Hg at the last recorded visit (still without rescue). Seven patients remained untreated for ≥3 years; their mean (±SD) IOP was 22.8 ± 1.5 mm Hg at baseline and 18.0 ± 4.1 mm Hg at the last recorded visit (still without rescue).

Reference
Medeiros FA, et al. Extended duration of IOP lowering with bimatoprost implant in a phase 3 open-label extension study. Presented at: ARVO 2021.

-Advertisement-
Related Articles
Compounded fixed-combination injection provides stable mydriasis during surgery
Aug 04, 2021
More research needed on link between strabismus and mental health disorders in kids
May 21, 2021
Patient demographics influence utilization of care for eye conditions
May 21, 2021
-Advertisement-
-Advertisement-
-Advertisement-
-Advertisement-
-Advertisement-